RECOMBINANT erIL-15 NK CELLS
AssigneesNantCell, Inc., NantBio, Inc., ImmunityBio, Inc.
InventorsPatrick Soon-Shiong, Shahrooz Rabizadeh, Kayvan Niazi, Hans G. Klingemann
Life of this patent
Estimating the term…
Abstract
Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.
Claims26
A method of stimulating a cell mediated immune response in a patient, the method comprising administering to the patient an effective amount of a composition comprising a genetically modified natural killer (NK) cell,
- wherein the genetically modified NK cell comprises a recombinant nucleic acid comprising a first segment encoding a long signal peptide LSP variant of Interleukin-15 (IL-15) as set forth in SEQ ID NO:
- 5,
- wherein the variant comprises an endoplasmic reticulum-retention signal (erLSP-IL-15).
A method of stimulating a cell mediated immune response in a patient, the method comprising administering to the patient an effective amount of a composition comprising a genetically modified natural killer NK cell,
- wherein the genetically modified NK cell comprises a recombinant nucleic acid comprising 1) a first segment encoding a long signal peptide LSP variant of Interleukin-15 (IL-15) as set forth in SEQ ID NO:
- 5, wherein the variant comprises an endoplasmic reticulum-retention signal (erLSP-IL-15);
- and 2) a second segment encoding a chimeric antigen receptor (CAR).
Dependencies are inferred from the claim text.